4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) (MoTriColor)
Date du début: 1 oct. 2015, Date de fin: 30 sept. 2019,
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different.We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assa ...
Voir le projet
12
Participants partenaires
TERMINÉ
Improved breast cancer care by innovative diagnostic test MammaPrint (MammaPrint)
Date du début: 1 juil. 2015, Date de fin: 30 juin 2017,
Agendia NV, a Dutch SME, was founded in 2003 as spin-off from the Netherlands Cancer Institute. They pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer. Agendia aims to be one of the key market players in genomic breast cancer profiling. One of the products Agendia is developing is MammaPrint, a breast cancer recurrence test. This test identifies the r ...
Voir le projet
1
Participant partenaire
TERMINÉ
Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet
8
Participants partenaires
TERMINÉ
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Voir le projet